AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26847975
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Analysis System of Psychotherapy (CBASP) plus Treatment As Usual (TAU), n=8
Trial: 26847975
Drug: Mindfulness-based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based Cognitive Therapy (MBCT) plus Treatment As Usual (TAU), n=9
Trial: 26847975
Drug: Treatment As
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment As Usual (TAU) only, n=8
Trial: 17620076
Drug: Grazax sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grazax sublingual immunotherapy
Trial: 1710098
Drug: Aprotinin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (4 x 10(6) KIU) as a continuous infusion and 2 x 10(6) KIU added to pump prime
Trial: 28716146
Drug: Weekly mobile
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly mobile phone text messaging plus motivational interviewing and usual standard of care
Trial: 21289601
Drug: acamprosate (2997
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acamprosate (2997 mg daily)
Trial: 19712767
Drug: CpG-containing malaria
RxNorm normalized name: Plasmodium malariae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CpG-containing malaria vaccine
Trial: 17200316
Drug: Alendronate (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (70 mg orally per week for three months)
Trial: 17200316
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy (Control Group B)
Trial: 1426388
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate plus gonadotropins (group L)
Trial: 30545350
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (long-acting muscarinic antagonist and long-acting β2-agonist/inhaled corticosteroid)
Trial: 30545350
Drug: Dual bronchodilator
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual bronchodilator (ICS withdrawal)
Trial: 23818351
Drug: XELOX chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: XELOX chemotherapy (3 cycles)
Trial: 16699814
Drug: 1 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg/day Pycnogenol
Trial: 10957700
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg ibuprofen per os and topical placebo
Trial: 10957700
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g of a 5% commercial ibuprofen gel topically applied and oral placebo capsules
Trial: 10957700
Drug: Peroral ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Peroral ibuprofen
Trial: 10957700
Drug: Commercial ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Commercial ibuprofen gel
Trial: 8771007
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) 4 IU/m2/day subcutaneously for 6 months
Trial: 6730991
Drug: Community treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community treatment provided by the Community Treatment Team, including comprehensive community treatment and a 24-h crisis service.
Trial: 6730991
Drug: Community treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community treatment (Experimental group).
Trial: 30044162
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg daily combined with metformin 500 mg three times daily (Group A)
Trial: 30044162
Drug: Simvastatin and
RxNorm normalized name: simvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin and metformin individually (Group B)
Trial: 30044162
Drug: Simvastatin and
RxNorm normalized name: simvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin and metformin individually (Group C)
Trial: 20697836
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (IIT) to maintain blood glucose levels from 80 to 110 mg/dl
Trial: 20697836
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment to maintain blood glucose levels less than 151 mg/dl
Trial: 11892710
Drug: Neridronate 200
RxNorm normalized name: Neridronate
DrugBank: Neridronic Acid (DB11620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neridronate 200 mg
Trial: 11892710
Drug: Neridronate 100
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neridronate 100 mg
Trial: 11892710
Drug: All Neridronate
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All Neridronate doses
Trial: 8967094
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1) infusion at a dosage of 60 micrograms over 2 hours
Trial: 4048832
Drug: Secretin infusion
RxNorm normalized name: Secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Secretin infusion (3 CU/kg/h)
Trial: 20692797
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise therapy (SET) with at least two training sessions per week, each lasting over 30 minutes during the first 3 months.
Trial: 20692797
Drug: SET involving
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SET involving only walking vs. a combination of exercises.
Trial: 15906080
Drug: Increase in
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in VO2max from 2.36 l min(-1) to 3.44 l min(-1)
Trial: 15906080
Drug: Increase in
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in VO2max from 4.77 l min(-1) to 6.36 l min(-1)
Trial: 7589684
Drug: Mast cell
RxNorm normalized name: Mast cell protease 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mast cell blocker (tranilast) 300 mg/d for 3 months
Trial: 2404878
Drug: 6‐monthly screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6‐monthly screening by chest X‐ray and sputum cytology
Trial: 7364521
Drug: No induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No induction (control) treatment
Trial: 25350973
Drug: Raltegravir with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir with optimized background therapy (OBT)
Trial: 23497575
Drug: Complex multifaceted
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex multifaceted intervention incorporating academic detailing, medicines review with web-based pharmaceutical treatment algorithms, and tailored patient information leaflets.
Trial: 20449934
Drug: Oral rapamycin
RxNorm normalized name: kanamycin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rapamycin plus bare metal stents (OR + BMS)
Trial: 28168845
Drug: Drug eluting
RxNorm normalized name: Drug eluting stent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug eluting stents (DES)
Trial: 9431344
Drug: Early operation
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early operation compared with intravenous antibiotics with or without drainage
Trial: 9431344
Drug: Delay in
RxNorm normalized name: Delayed Release Oral Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delay in treatment
Trial: 8172795
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy (timing of quality of life assessment)
Trial: 25596659
Drug: Chemoradiotherapy (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy (two cycles of cisplatin 100 mg/m(2) during radiotherapy)
Trial: 25596659
Drug: Radiotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy plus panitumumab (three cycles of panitumumab 9 mg/kg every 3 weeks administered with radiotherapy)
Trial: 17608028
Drug: FavId, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FavId, a patient-specific idiotypic vaccine
Trial: 11252687
Drug: Rofecoxib (Vioxx)
RxNorm normalized name: rofecoxib Oral Suspension [Vioxx]
DrugBank: Rofecoxib (DB00533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rofecoxib (Vioxx) 12.5 mg qd
Trial: 11252687
Drug: Arthrotec (diclofenac
RxNorm normalized name: Arthrotec (diclofenac sodium (enteric coated core) 50 MG / miSOPROStol (non-enteric coated mantle) 200 MCG) Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthrotec (diclofenac 50 mg/misoprostol 200 mcg bid)
Trial: 7997000
Drug: 0.3% d-phenothrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% d-phenothrin lotion
Trial: 11027424
Drug: CarboMIP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CarboMIP regimen (cisplatin 60 mg m(‐2) and carboplatin 200 mg m(‐2) with mitomycin 6 mg m(‐2) and ifosfamide 3 g m(‐2))
Trial: 11027424
Drug: MIP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIP regimen (cisplatin 50 mg m(‐2) with mitomycin 6 mg m(‐2) and ifosfamide 3 g m(‐2))
Trial: 8017600
Drug: Continuous regional
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous regional analgesia (interpleural and epidural infusions)
Trial: 8017600
Drug: Intravenous opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous opioid administration
Trial: 3065741
Drug: Chlorambucil (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorambucil (daily indefinite course)
Trial: 16131531
Drug: Morphine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (100 microg/kg + 10 microg/kg/h)
Trial: 16131531
Drug: Additional morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional morphine
Trial: 11084248
Drug: Aflurax (pectin-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflurax (pectin-based anti-reflux formulation)
Trial: 27465906
Drug: Enteric-coated formulation
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated formulation
Trial: 27465906
Drug: Second formulation
RxNorm normalized name: 60 Second
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second formulation prototype (single-unit core and enteric-coating film)
Trial: 23740231
Drug: Naproxen (NPX)
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen (NPX) 1000 mg/d
Trial: 23039926
Drug: Multi-tiered oral
RxNorm normalized name: Finafta Multi Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-tiered oral health education programme
Trial: 15835284
Drug: Modified Constraint-Induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Constraint-Induced Movement Therapy (m-CIMT)
Trial: 12781934
Drug: Medication self-management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication self-management program
Trial: 10475621
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy and bone marrow transplant with HLA-identical sibling donor
Trial: 10475621
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy and bone marrow transplant with alternative donor (non-HLA-identical sibling)
Trial: 10475621
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy and bone marrow transplant with autotransplant
Trial: 10475621
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (interferon and/or chemotherapy)
Trial: 6126894
Drug: Metipranolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metipranolol (5 mg)
Trial: 6126894
Drug: Metipranolol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metipranolol (20 mg)
Trial: 31013204
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 mg/kg Dextrose)
Trial: 29244251
Drug: B vitamin
RxNorm normalized name: B-50 Hi Potency B Vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B vitamin supplementation (folic acid 2.5 mg/day, vitamin B6 50 mg/day, vitamin B12 1 mg/day)
Trial: 25833778
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg of anthocyanins twice daily
Trial: 17220905
Drug: Fludarabine (Flu)
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine (Flu) 40 mg/m(2)/day x 5 days
Trial: 17220905
Drug: Cladribine (Clad)
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine (Clad) 10 mg/m(2)/day x 5 days plus oral busulfan (1 mg/kg q6 h x 2 days) and total body irradiation 200 cGy
Trial: 15079003
Drug: Enzyme replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme replacement therapy (ERT) with agalsidase beta
Trial: 2751738
Drug: Isosorbide‐5‐mononitrate sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide‐5‐mononitrate sustained-release capsules (Olicard 40 retard)
Trial: 2751738
Drug: Standard‐release formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard‐release formulation of isosorbide‐5‐mononitrate
Trial: 155098
Drug: Timolol, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol, administered twice a day
Trial: 155098
Drug: Pilocarpine, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilocarpine, administered four times a day
Trial: 18346976
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) treatment
Trial: 28130888
Drug: Warm lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm lidocaine and tetracaine patch
Trial: 23157172
Drug: Low-salt treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-salt treatment 6.6 mg/m(3)
Trial: 23157172
Drug: High-salt treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-salt treatment 10.8 mg/m(3)
Trial: 23157172
Drug: Placebo 0.3
RxNorm normalized name: Norethindrone;Placebo 0.35 MG; NA Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 0.3 mg/m(3)
Trial: 18615480
Drug: CC haplotype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC haplotype of ERCC1
Trial: 10423632
Drug: 60 microg
RxNorm normalized name: Filgrastim 960 microgram/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 microg PGE (1) administered intravenously (i.v.) in 100 mL saline solution over 2 hours each day for 14 days.
Trial: 10423632
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intravenously (i.v.) in 100 mL saline solution over 2 hours each day for 14 days.
Trial: 3549323
Drug: Zopiclone 7.5
RxNorm normalized name: zopiclone 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zopiclone 7.5 mg given orally at bedtime for 7 consecutive days
Trial: 3549323
Drug: Triazolam 0.5
RxNorm normalized name: triazolam 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam 0.5 mg given orally at bedtime for 7 consecutive days
Trial: 30043714
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg tamsulosin plus 10 mg tadalafil daily for 7 days
Trial: 30043714
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg tamsulosin plus placebo
Trial: 22651946
Drug: Guideline-based parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-based parenteral hydration therapy
Trial: 18822977
Drug: Acupoint-injection group
RxNorm normalized name: meningococcal group B vaccine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint-injection group (2 mg Morphine into bilateral Neiguan (PC 6))
Trial: 18822977
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection group (5 mg Morphine)
Trial: 18822977
Drug: Hypodermic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypodermic injection group (5 mg Morphine)
Trial: 14695923
Drug: CoQ10 100
RxNorm normalized name: Walgreens CoQ10 100mg Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ10 100 mg t.i.d.
Trial: 27488394
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg ramosetron
Trial: 11348910
Drug: Transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal fentanyl
Trial: 11911558
Drug: Tramadol/acetaminophen
RxNorm normalized name: TRAMADOL/ACETAMINOPHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol/acetaminophen
Trial: 22760642
Drug: Milk fortified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk fortified with 10 mg Fe/L as ferrous sulfate
Trial: 22760642
Drug: Milk fortified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk fortified with 10 mg Fe/L and 5 mg Zn/L as Zn sulfate
Trial: 22760642
Drug: Milk fortified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk fortified with 10 mg Fe/L and 10 mg Zn/L as Zn sulfate
Trial: 22760642
Drug: Milk fortified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk fortified with 10 mg Fe/L and 20 mg Zn/L as Zn sulfate
Trial: 22760642
Drug: Milk fortified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk fortified with 10 mg Fe/L and ascorbic acid (70 mg/L)
Trial: 22760642
Drug: Milk fortified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk fortified with 10 mg Fe/L and 5 mg Zn/L as Zn sulfate and ascorbic acid (70 mg/L)
Trial: 22760642
Drug: Milk fortified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk fortified with 10 mg Fe/L and 10 mg Zn/L as Zn sulfate and ascorbic acid (70 mg/L)
Trial: 22760642
Drug: Milk fortified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk fortified with 10 mg Fe/L and 20 mg Zn/L as Zn sulfate and ascorbic acid (70 mg/L)
Trial: 12133500
Drug: Bifendate (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifendate (higher doses: 30-45 mg/d for ages <= 12, 45-67.5 mg/d for ages > 12) for up to 12 months
Trial: 12133500
Drug: Bifendate (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifendate (higher doses)
Trial: 7575719
Drug: Monoclonal antibody
RxNorm normalized name: Monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody (MAb) CAMPATH‐1H treatment
Trial: 1710655
Drug: High-dose cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cisplatin (40 mg/m2 daily for 5 days)
Trial: 1710655
Drug: Standard-dose cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose cisplatin (20 mg/m2 daily for 5 days)
Trial: 8113843
Drug: High-dose cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cisplatin
Trial: 1710655
Drug: Standard-dose cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose cisplatin
Trial: 7233157
Drug: High sodium
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High sodium water (107 mg Na/L)
Trial: 30293198
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (70 µg [2800 IU] daily for 3 months)
Trial: 27798013
Drug: PCV7 (7-valent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV7 (7-valent pneumococcal conjugate vaccine)
Trial: 19129748
Drug: Dapagliflozin (2.5-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (2.5-100 mg daily for 14 days)
Trial: 19129748
Drug: Dapagliflozin (20-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (20-50 mg)
Trial: 15512856
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg PAS
Trial: 15512856
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg PAS
Trial: 15512856
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg PAS
Trial: 11158017
Drug: Hormonal replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal replacement therapy (estradiol valerate at 2 mg/day for 11 days and cyproterone acetate at 1 mg/day for 10 days; group C)
Trial: 11158017
Drug: Estradiol alone
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol alone (patches with E(2) release of 50 microg/24 h; group B)
Trial: 8002638
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (group A)